Two-step tuberculin skin testing of injection drug users recruited from community-based settings

International Journal of Tuberculosis and Lung Disease

Volumn 1, Issue 2, 1997, Pages 128-134

  Lifson, A R ^a   Grant, S M ^a   Lorvick, J ^b   Pinto, F D ^c   He, H ^d   Thompson, S ^b   Keudell, E G ^e   Stark, M J ^e   Booth, R E ^c   Watters, J K ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Oregon Health Division   (United States)

^e MULTNOMAH COUNTY HEALTH DEPARTMENT   (United States)

Author keywords

Booster effect; HIV; Injection drug users; Tuberculin testing; Two step testing

Indexed keywords

ADULT; ARTICLE; CLINICAL TRIAL; COMMUNITY CARE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; ETHNIC GROUP; FEMALE; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; RACE; RISK FACTOR; SERODIAGNOSIS; STATISTICAL MODEL; STATISTICS; SUBSTANCE ABUSE; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES;

ADULT; CALIFORNIA; COLORADO; COMMUNITY HEALTH SERVICES; CONTINENTAL POPULATION GROUPS; CROSS-SECTIONAL STUDIES; ETHNIC GROUPS; FEMALE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; MIDDLE AGED; OREGON; PREVALENCE; RISK FACTORS; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0031107711     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Centers for Disease Control and Prevention. Essential components of A tuberculosis prevention and control program; and Screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1995; 44 (No. RR-11). 1-34.
2. American Thoracic Society. Control of tuberculosis in the United States. Am Rev Respir Dis 1992; 146: 1623-1633.
3. Huebner R E, Schein M F, Bass J B. The tuberculin skin test. Clin Infect Dis 1993; 17: 968-975.
4. Centers for Disease Control. Screening for tuberculosis and tuberculosis infection in high-risk populations, and The use of preventive therapy for tuberculous infection in the United States: recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR 1990; 39 (No. RR-8): 1-12.
5. Reichman L B, Felton C P, Edsall J R. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med 1979; 139: 337-339.
6. Perlman D C, Salomon N, Perkins M P, Yancovitz S, Paone D, Des Jarlais D C. Tuberculosis in drug users. Clin Infect Dis 1995; 21: 1253-1264.
7. Selwyn P A, Hartel D, Lewis V A, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-550.
8. Centers for Disease Control. Tuberculosis prevention in drug-treatment centers and correctional facilities - selected U.S. sites, 1990-1991. MMWR 1993; 42: 210-213.
9. Centers for Disease Control and Prevention. Prevention and control of tuberculosis in correctional facilities: Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1996; 45 (no. RR-8): 1-27.
10. Centers for Disease Control. Prevention and control of tuberculosis among homeless persons: Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1992; 41 (no. RR-5): 13-23.
11. Alvarcz S, Kasprzyk D R, Freundl M. Two-stage skin testing for tuberculosis in a domiciliary population. Am Rev Respir Dis 1987; 136: 1193-1196.
12. Rosenberg T, Manfreds J, Hershfield E S. Two-step tuberculin testing in staff and residents of a nursing home. Am Rev Respir Dis 1993; 148: 1537-1540.
13. Richards N M, Nelson K E, Batt M D, Hackbarth D, Heidenreich J G. Tuberculin test conversion during repeated skin testing, associated with sensitivity to nontuberculous mycobacteria. Am Rev Respir Dis 1979; 120: 59-65.
14. Thompson N J, Glassroth J L, Snider D E, Farer L S. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979; 119: 587-597.
15. Bass J B, Serio R A. The use of repeat skin tests to eliminate the booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1981; 123: 394-396.
16. Valenti W M, Andrews B A, Presley B A, Reifler C B. Absence of the booster phenomenon in serial tuberculin skin testing. Am Rev Respir Dis 1982; 125: 323-325.
17. Menzies R, Vissandjee B, Rocher I, St. Germain Y. The booster effect in two-step tuberculin testing among young adults in Montreal. Ann Intern Med 1994; 120: 190-198.
18. Wenzel M. An alternative to 'two-step' tuberculin skin testing for Southeast Asian refugees. Nurse Practitioner 1991; 16: 25-28.
19. Cauthen G M, Snider D F, Onorato I M. Boosting of tuberculin sensitivity among Southeast Asian refugees. Am J Respir Crit Care Med 1994; 149: 1597-1600.
20. Sepulveda R L, Burr C, Ferrer X, Sorensen R U. Booster effect of tuberculin testing in healthy 6-year-old children vaccinated with Bacillus Calmette-Guérin at birth in Santiago, Chile. Ped Infect Dis 1988; 7: 578-581.
21. Sepulveda R L, Ferrer X, Latrach C, Sorensen R U. The influence of Calmette-Guérin Bacillus immunization on the booster effect of tuberculin testing in healthy young adults. Am Rev Respir Dis 1990; 142: 24-28.
22. Johnsen C. Evaluation of two-step tuberculin testing in a Massachusetts correctional facility. Am J Infect Control 1995; 23: 209-212.
23. Webster C T, Gordin F M, Matts J P, et al. Two-stage tuberculin skin testing in individuals with human immunodeficiency virus infection. Am J Respir Crit Care Med 1995; 151: 805-808.
24. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. MMWR 1994; 43 (No. RR-13): 1-132.
25. Watters J K, Biernacki P. Targeted sampling: options for the study of hidden populations. Social Prob 1989; 36: 416-430.
26. Booth R E, Watters J K, Chitwood D D. HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack. Am J Public Health 1993; 83: 1144-1148.
27. Booth R E. Predictors of unsafe needle practices: injection drug users in Denver. J Acquir Immune Def Syndr 1994; 7: 504-508.
28. Watters J K, Estilo M, Clark G L, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994; 271: 115-120.
29. Sokal J E. Measurement of delayed skin-test responses. N Engl J Med 1975; 293: 501-502.
30. Graham N M H, Nelson K E, Solomon L, et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA 1992; 267: 369-373.
31. Markowitz N, Hansen N I, Wilcosky T C, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993; 119: 185-193.
32. Chaparas S D, Vandiviere H M, Melvin I, Koch G, Becker C. Tuberculin test: variability with the Mantoux procedure. Am Rev Respir Dis 1985; 132: 175-177.
33. Edwards L B, Acquaviva F A, Livesay V T. Identification of tuberculous infected: dual tests and density of reaction. Am Rev Respir Dis 1973; 108: 1334-1339.
34. Snider D E. Bacille Calmette-Guérin vaccinations and tuberculin skin tests. JAMA 1985; 253: 3438-3439.
35. Bagasra O, Forman L. Functional analysis of lymphocytes subpopulations in experimental cocaine abuse. I. Dose-dependent activation of lymphocyte subsets. Clin Exp Immunol 1989; 77: 289-293.
36. Peterson P K, Sharp B, Gekker G, Brummitt C, Keane W F. Opioid-mediated suppression of interferon-γ production by cultured peripheral blood mononuclear cells. J Clin Invest 1987; 80: 824-831.
37. Bermudez L E, Young L S. Ethanol augments intracellular survival of Mycobacterium avium complex and impairs macrophage responses to cytokines. J Infect Dis 1991; 163: 1286-1292.
38. McMurray D N, Bartow R A. Immunosuppression and alteration of resistance to pulmonary tuberculosis in guinea pigs by protein undernutrition. J Nutr 1992; 122: 738-743.
39. American Thoracic Society. The tuberculin skin test. Am Rev Respir Dis 1981; 124: 356-363.
40. Hahn R A, Onorato I M, Jones T S, Dougherty J. Prevalence of HIV infection among intravenous drug users in the United States. JAMA 1989; 261: 2677-2684.
41. Lampinen T M, Joo E, Seweryn S, Hershow R C, Wiebel W. HIV seropositivity in community-recruited and drug treatment samples of injecting drug users. AIDS 1992; 6: 123-126.
42. Metzger D S, Woody G E, McLellan A T, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993; 6: 1049-1056.
43. Goldstein S, Perlman D C, Salomon N. Two-stage tuberculin skin testing in an HIV-infected population: a preliminary report. Mt. Sinai J Med 1994; 61: 337-340.